UNASSIGNED: Patients who have undergone low anterior resection will be approached for this study. On patient\'s visit, complaints regarding the defecation as well as any deterioration in their overall quality of life will be assessed using questionnaires such as the Low Anterior Resection Syndromes score, Wexner score, European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) CR-29, and Measure Yourself Medical Outcome Profile tool. Few additional target questions will be also asked, such as \"Would you recommend the treatment to anybody; did you expect the improvement following the treatment; etc.\" Questionnaires and scales will be filled on follow-up visits every 3 months for 1 year.
UNASSIGNED: This multicenter, randomized controlled trial will lead to a better understanding of LARS treatment. Moreover, it will be a hypothesis-generating study and will inform areas needing future prospective studies.
UNASSIGNED: ClinicalTrials.gov, identifier (NCT05920681).
■接受过低位前切除术的患者将进行这项研究。在病人的访问,有关排便以及其整体生活质量恶化的投诉将使用问卷进行评估,例如低前切除综合征评分,Wexner得分,欧洲癌症研究和治疗组织(EORTC)生活质量(QOL)CR-29和测量自己的医疗结果配置文件工具。很少还会提出其他目标问题,如“你会向任何人推荐治疗吗?你是否期望治疗后有所改善;等等。“问卷和量表将每3个月填写一次随访,为期1年。
■这个多中心,随机对照试验将使人们更好地理解LARS治疗.此外,这将是一项产生假设的研究,并将为需要未来前瞻性研究的领域提供信息。
■ClinicalTrials.gov,标识符(NCT05920681)。